Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aus-131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 7/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.74 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.74 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aus-131 SCHEMBL677723 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL2002128 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43647 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43648 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL17591903 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL31545730 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL19861143 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL17679253 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL30720187 | 0.90 | ESR2 (0.82) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL4360255 | 0.90 | ESR2 (0.82) | ESR2ESR1TTRALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122060694-A | Mutant for efficiently synthesizing S-equol and whole-cell transformation system | 生合万物(上海)生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12589109-B2 | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-03-31 | — | — | US | disclosed |
| CN-121628799-A | Genetically engineered bacterium for producing (S) -equol and application thereof | 杭州合碳创物科技有限公司 | 2026-03-10 | — | — | CN | disclosed |
| CN-121628799-A | Genetically engineered bacterium for producing (S) -equol and application thereof | 杭州合碳创物科技有限公司 | 2026-03-10 | — | — | CN | disclosed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| CN-121160648-A | Tetrahydrodaidzein reductase mutant and application thereof in synthesis of (S) -equol | 沈阳药科大学 | 2025-12-19 | — | — | CN | disclosed |
| CN-121160648-A | Tetrahydrodaidzein reductase mutant and application thereof in synthesis of (S) -equol | 沈阳药科大学 | 2025-12-19 | — | — | CN | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250302864-A1 | METHODS FOR TREATING ALZHEIMER’S DISEASE | CYCLO THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250230416-A1 | MULTI DONOR STEM CELL COMPOSITIONS AND METHODS OF MAKING SAME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2023119230-A1 | COAGULATION PATHWAY AND NICOTINAMIDE-ADENINE DINUCLEOTIDE PATHWAY MODULATING COMPOSITIONS AND METHODS OF THEIR USE | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| CN-115747240-A | Recombinant escherichia coli engineering strain for producing equol and application | 华熙生物科技股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-111574487-B | Preparation method of chiral dihydroisoflavone compound and product thereof | 深圳市宝安区新材料研究院 | 2023-02-21 | — | — | CN | disclosed |
| US-20220370529-A1 | CANNABIS COMPOSITIONS AND RELATED METHODS | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2022-11-24 | — | — | US | disclosed |
| WO-2022208169-A1 | PULSATILE PROTOCOLS FOR CANCER TREATMENT METHODS AND USES | CLINICS OPERATIONS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022186355-A1 | COMPOSITION FOR PRODUCTION OF 6,3'-DIHYDROXYEQUOL | 株式会社ダイセル | 2022-09-09 | — | — | WO | disclosed |
| WO-2022124311-A1 | FEMALE HORMONE-LIKE ACTIVITY ENHANCER | 小林製薬株式会社 | 2022-06-16 | — | — | WO | disclosed |
| CN-114423420-A | Methods and compositions for producing phytonutrients in microbiome | 捷通国际有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022051631-A1 | THERAPY TO STIMULATE HIPPOCAMPAL NEURAL PROGENITORS AND ADULT NEUROGENESIS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589109-B2 | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis | DCX, PSEN1, CSNK1D | ESR2 2685/4885ESR1 4088/4885TTR 1283/4885 |
| US-20250302864-A1 | METHODS FOR TREATING ALZHEIMER’S DISEASE | PSEN2, PSEN1, ACHE | ESR2 3194/4885ESR1 3884/4885TTR 97/4885 |
| US-20220370529-A1 | CANNABIS COMPOSITIONS AND RELATED METHODS | CNR2, CNR1, S100P | ESR2 4714/4885ESR1 4729/4885TTR 2262/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ESR2 3386/4885ESR1 2358/4885TTR 141/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ESR2 3386/4885ESR1 2358/4885TTR 141/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | ESR2 681/4885ESR1 838/4885TTR 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.